CMSC: Natalizumab for MS During the Covid-19 Pandemic
Overall outcomes good after Covid infection, vaccine for most patients At the recent Consortium of...
Read MoreJan 5, 2022
Overall outcomes good after Covid infection, vaccine for most patients At the recent Consortium of...
Read MoreDec 30, 2021
GI disorders most common reason for Tx discontinuation Safety is always a concern for any...
Read MoreDec 29, 2021
Prescribers cite tolerability when switching from other DMTs For those who doubt the effectiveness...
Read MoreDec 22, 2021
Focus on Multiple Sclerosis CMSC eBook
Read More